Skip to content
B
BiotechEdge
Start 14-Day Free Trial

Soleno Therapeutics + Neurocrine Biosciences

pending

$SLNO acquired by Neurocrine Biosciences for $2.9B

Deal Summary

Deal Value
$2.9B
Price/Share
$53
Announced
Apr 6, 2026
Expected Close
TBD

Fund Positioning

8 of 20 tracked specialist biotech funds held $SLNO — based on SEC 13F filings.

FundSharesValueEntryAt Announcement
Avoro Capital Advisors2.9M$134.3MMar 2025Yes
Commodore Capital1.2M$55.6MMar 2025Yes
Deep Track Capital1.0M$46.3MDec 2025Yes
Perceptive Advisors430K$36.1MMar 2025Yes
RTW Investments424K$35.6MJun 2025Yes
Eventide Asset Management467K$31.6MSep 2025Yes
Rock Springs Capital247K$11.4MMar 2025Yes
Driehaus Capital13K$0.9MMar 2025Yes
← All biotech acquisitions